ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » AMGN Stock Price » AMGN Stock News

Amgen Inc. Share News

 Amgen Inc. (mm) Stock Price
AMGN Stock Price
 Amgen Inc. (mm) Stock Chart
AMGN Stock Chart
 Amgen Inc. (mm) Stock News
AMGN Stock News
 Amgen Inc. (mm) Company Information
AMGN Company Information
 Amgen Inc. (mm) Stock Trades
AMGN Stock Trades

NPS Pharma to Receive $25 Million from Amgen for Royalty Rights for Sensipar

By Victoria Stilwell NPS Pharmaceuticals Inc. (NPSP) will receive a one-time $25 million payment this month in exchange for its rights to receive royalties earned after 2018 for sales of its Sensipar drug under an amended license agreement with Amgen Inc. (AMGN). Sensipar, marketed as Mimpara in Europe, treats secondary hyperparathyroidism in chronic kidney disease patients on dialysis. In 1996 NPS licensed world-wide rights to Amgen to develop and commercialize the drug, and the drug received FDA approval in March 2004. NPS said funds from the agreement are expected to support the launches of both Gattex, a treatment for short bowel syndrome, and Natpara, which is intended to be used for adult hypoparathyroidism, in addition to aiding its transition into a self-sustaining commercial-stage business. The deal is expected to accelerate cash flow with at least $75 million of incremental cash expected through 2013. The amendment also extends the royalty-advance-repayment period, limiting the offset of the royalty advance that the biopharmaceutical company received from Amgen in August 2011 to $8 million a quarter. After repayment of the advance and a 9% anum discount factor on the balance of $92 million, Amgen will resume paying NPS all royalties earned through 2018. "This innovative transaction underscores our commitment to accessing capital at the lowest possible cost and in a manner that is in the best interests of our shareholders," said Luke M. Beshar, NPS's chief financial officer. Shares of NPS were inactive in premarket trade at $8.61, while shares of Amgen slipped 0.2% to $72.75. NPS is up 31% so far this year, while Amgen is up 14%. Write to Victoria Stilwell at

Stock News for Amgen Inc. (AMGN)
10/24/201616:00:00Amgen Announces Webcast Of 2016 Third Quarter Financial Results
10/20/201616:19:00Amgen Announces Positive Top-Line Results From XGEVA® (Denosumab...
10/14/201616:10:03Current Report Filing (8-k)
10/14/201616:05:00Amgen Announces 2016 Fourth Quarter Dividend
10/14/201616:00:00Amgen Announces Appointment Of Ellen J. Kullman To Board Of Directors
10/10/201609:09:00New Retrospective Analyses Confirm Vectibix® (Panitumumab) Treatment...
10/05/201616:10:00New Amgen Data In Melanoma And Metastatic Colorectal Cancer To...
10/04/201616:00:00Amgen To Participate In Citi Biotech R&D Conference Call
10/03/201616:09:00Study Results Published In Journal of Clinical Oncology Show...
09/29/201609:51:00Amgen, Arrowhead Pharma Agree to Cardiovascular Collaboration
09/29/201607:30:00Amgen And Arrowhead Pharmaceuticals Announce Two Cardiovascular...
09/28/201616:30:00Amgen Announces Erenumab Significantly Reduces Monthly Migraine...
09/27/201608:32:00Amgen's Myeloma Treatment Study Fails to Meet Primary Endpoint
09/27/201604:00:00Amgen Announces Top-Line Results From Phase 3 KYPROLIS® (Carfilzomib...
09/26/201617:00:00Amgen Opens Nomination Process For LabCentral Residency
09/26/201616:00:00Amgen And UCB Announce U.S. FDA Acceptance Of Biologics License...
09/23/201620:12:00FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23/201619:10:00FDA Approves Amgen's Biosimilar Version of Humira -- Update
09/23/201618:56:00FDA Approves Amgen's Biosimilar Version of Humira
09/23/201618:04:00FDA Approves Amgen's AMJEVITA™ (Adalimumab-Atto) For Treatment O...

Amgen Inc. and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations